Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 15;205(12):1476-1479.
doi: 10.1164/rccm.202109-2026LE.

Impaired Humoral and Cellular Responses to COVID-19 Vaccine in Heart and Lung Transplant Recipients

Vicky Gerovasili  1   2 , Anand Shah  1   2 , Aran Singanayagam  2 , Peter M George  1   2 , Raymond Njafuh  1 , Maria Prendecki  3   4 , Martin Carby  1 , Michelle Willicombe  3   4 , Peter Kelleher  1   5   6 , Anna Reed  1   2
Affiliations

Impaired Humoral and Cellular Responses to COVID-19 Vaccine in Heart and Lung Transplant Recipients

Vicky Gerovasili et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Serological response after vaccination (BAU/ml) in 58 cardiothoracic transplant recipients and 68 naive healthcare workers (HCW) according to vaccine type. Highly immunosuppressed cardiothoracic transplant recipients (HICTTR) had significantly lower serology levels (P < 0.0001). Asterisks indicate outliers. (B) T-cell levels following vaccination (peripheral blood mononuclear cells per million) in 58 HICTTR and 67 HCW according to vaccine type. HICTTR had significantly lower T-cell concentrations (P < 0.0001). (C) Seroconversion rate and T-cell response in 58 HICTTR subjects following vaccination according to vaccine type. Vaccination with the BNT162b2 vaccine resulted in a significantly higher probability of seroconversion than the ChAdOx1 vaccine (12/27 [44%] and 3/31 [10%], respectively; P = 0.003). There was no difference in the T-cell detection rate after vaccination with the BNT162b2 compared with the ChAdOx1 vaccine (5/27 [19%] and 7/31 [23%], respectively; P = 0.58). For A and B, values have been log-transformed. BAU = binding antibody units; PBMC = peripheral blood mononuclear cells; SFU = spot forming units.
See this image and copyright information in PMC

References

    1. Ravanan R, Callaghan CJ, Mumford L, Ushiro-Lumb I, Thorburn D, Casey J, et al. SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: a national cohort study. Am J Transplant . 2020;20:3008–3018. - PMC - PubMed
    1. Saez-Giménez B, Berastegui C, Barrecheguren M, Revilla-López E, Los Arcos I, Alonso R, et al. COVID-19 in lung transplant recipients: a multicenter study. Am J Transplant . 2021;21:1816–1824. - PMC - PubMed
    1. Narasimhan M, Mahimainathan L, Clark AE, Usmani A, Cao J, Araj E, et al. serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines. Vaccines (Basel) . 2021;9:708. - PMC - PubMed
    1. Crespo-Leiro MG, Barge-Caballero E, Gustafsson F. Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore. Eur J Heart Fail . 2021;23:1560–1562. - PMC - PubMed
    1. Prendecki M, Thomson T, Clarke C, Martin P, Gleeson S, Rute C, et al. in collaboration with the OCTAVE Study Consortium Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. Lancet . 2021;398:1482–1484. - PMC - PubMed

Publication types